Literature DB >> 10501249

Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).

F Estevez1, A Carr, L Solorzano, O Valiente, C Mesa, O Barroso, G V Sierra, L E Fernandez.   

Abstract

Certain gangliosides are tumor-associated antigens that constitute potential targets for cancer immunotherapy. A major drawback in the design of ganglioside-based cancer vaccines, however, is the poor immunogenicity of these glycolipids. Here we report the immunological and physicochemical properties of very small size proteoliposomes (VSSP) obtained by using anionic detergents to incorporate gangliosides into the outer membrane protein complex (OMPC) of N. meningitidis. VSSP of three different gangliosides, GM3, NGcGM3 and GD3, were tested. These gangliosides differ in level of expression in normal tissues and in immunogenicity in different animal species. We show that the immunization with VSSP in an oil adjuvant consistently induced both IgM and IgG anti-ganglioside antibodies. In the mouse, the anti-ganglioside IgG fraction was not restricted to the typical T-independent isotype IgG3. Unexpectedly, significant levels of the T-dependent IgG1, IgG2a and particularly IgG2b were also found. VSSP-mediated enhancement of the immunogenicity was not restricted to the relatively immunogenic ganglioside GD3, satisfactory immune responses against highly tolerated GM3 and NGcGM3 were also obtained. Similar results were achieved in chickens and monkeys. No reactogenicity was observed even when self-gangliosides were used for immunization. VSSP overcame natural tolerance to gangliosides in an adjuvant dependent fashion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501249     DOI: 10.1016/s0264-410x(99)00219-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

Authors:  C Venier; M D Guthmann; L E Fernández; L Fainboim
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse.

Authors:  Qianli Wang; Zhifang Zhou; Shouchu Tang; Zhongwu Guo
Journal:  ACS Chem Biol       Date:  2011-11-01       Impact factor: 5.100

3.  Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Authors:  Mayrel Labrada; Isabel Pablos; Francesca Prete; Giselle Hevia; Marilyn Clavell; Federica Benvenuti; Luis E Fernández
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?

Authors:  Fatemeh Farjadian; Mohsen Moghoofei; Soroush Mirkiani; Amir Ghasemi; Navid Rabiee; Shima Hadifar; Ali Beyzavi; Mahdi Karimi; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

Review 5.  Serum Antibodies to Glycans in Peripheral Neuropathies.

Authors:  Sandro Sonnino; Elena Chiricozzi; Maria Grazia Ciampa; Laura Mauri; Alessandro Prinetti; Gino Toffano; Massimo Aureli
Journal:  Mol Neurobiol       Date:  2016-02-11       Impact factor: 5.590

6.  Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.

Authors:  Yanbin Pan; Peter Chefalo; Nancy Nagy; Clifford Harding; Zhongwu Guo
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

Review 7.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 8.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 9.  NGcGM3/VSSP vaccine as treatment for melanoma patients.

Authors:  Kirenia Pérez; Marta Osorio; Julio Hernández; Adriana Carr; Luis Enrique Fernández
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

10.  Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers.

Authors:  Zhifang Zhou; Mohabul Mondal; Guochao Liao; Zhongwu Guo
Journal:  Org Biomol Chem       Date:  2014-04-14       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.